Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases.

Authors

Sohrab Arora, Henry Ford HealthFollow
Akshay Sood, Henry Ford HealthFollow
Deepansh Dalela, Henry Ford HealthFollow
Hoang J. Tang, Henry Ford HealthFollow
Amit Patel, Henry Ford Health
Jacob Keeley, Henry Ford HealthFollow
Quoc-Dien Trinh
Craig G. Rogers, Henry Ford HealthFollow
Mani Menon, Henry Ford HealthFollow
Firas Abdollah, Henry Ford HealthFollow

Recommended Citation

Arora S, Sood A, Dalela D, Tang HJ, Patel A, Keeley J, Trinh QD, Rogers CG, Menon M, and Abdollah F. Cytoreductive nephrectomy: Assessing the generalizability of the CARMENA trial to real-world national cancer data base cases. Eur Urol 2018; 75(2):352-353.

Document Type

Article

Publication Date

2-1-2019

Publication Title

European urology

Medical Subject Headings

Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Databases, Factual; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Nephrectomy; Research Design; Retrospective Studies; Sunitinib; Time Factors; Treatment Outcome

PubMed ID

30420256

Volume

75

Issue

2

First Page

352

Last Page

353